CClinicalTrials.gg
Status unknownNCT03071185Updated Nov 25, 2022

The Efficacy and Safety of Lower Limb Nerve Blocks in Postoperative Analgesia for the Free Flap Donor Sites

An interventional study of femoral nerve block, common peroneal nerve block in Elective Reconstructive Surgery and Pain, Post Operative, sponsored by Xia Zhang. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-25.

Sponsored by Xia Zhang · Not applicable, Interventional, and Supportive care

The sponsor has not verified this record recently (last verified Nov 2022), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The use of free fibular flaps and anterolateral thigh (ALT) flaps for repairing the oromandibular defects is well established, whereas few attentions were focused on postoperative analgesia for the donor area. Dexmedetomidine is a more selective and shorter-acting α2 adrenergic receptor. The purpose of this trial is to determine if using lower limb nerve blocks in patients undergoing free flap-based oromandibular reconstruction can significantly decrease use of pain medications and to evaluate the safety of lower limb nerve blocks. We also investigated the effect of adding dexmedetomidine as additive in femoral nerve blocks for postoperative analgesia.

Patients with oromandibular defects who were scheduled for elective reconstructive surgery using free fibular or ALT flaps, were divided into three groups in a randomized, single-blind fashion. In Group PCA, only intravenous patient controlled analgesia (PCA) was used postoperatively. In Group PCA+B, both intravenous PCA and lower limb blocks were used. In Group PCA+B+D, both intravenous PCA and lower limb blocks with dexmedetomidine as additivewere used. Post-operative narcotic usage, post-operative pain score, post-operative anti-emetic usage, vital signs, onset and duration of sensory and motor block, the presence of adverse effects such as nausea and vomiting were recorded.

Read the detailed description

The use of free fibular flaps and anterolateral thigh (ALT) flaps for repairing the oromandibular defects is well established, whereas few attentions were focused on postoperative analgesia for the donor area. Conventional postoperative pain management following oromandibular reconstruction consists of systemic opioids, which can cause nausea, vomiting, pruritus, urinary retention, constipation and respiratory depression. Adequate postoperative analgesia decreases the incidence of cardiopulmonary complications. Peripheral nerve blocks can attenuate the sensory innervations.The purpose of this trial is to determine if using lower limb nerve blocks in patients undergoing free flap-based oromandibular reconstruction can significantly decrease use of pain medications and to evaluate the safety of lower limb nerve blocks.

Patients with oromandibular defects, who were scheduled for elective reconstructive surgery using free fibular or ALT flaps, were divided into three groups in a randomized, single-blind fashion. In Group PCA, only intravenous patient controlled analgesia (PCA) was used postoperatively. In Group PCA+B, both intravenous PCA and lower limb blocks were used.In Group PCA+B+D, both intravenous PCA and lower limb blocks with dexmedetomidine as additivewere used. For patients with fibular flaps harvested, femoral nerve block and common peroneal nerve with ropivacaine were administered. For patients with ALT flaps harvested, femoral nerve block with ropivacaine was administered. Post-operative narcotic usage, post-operative pain score, post-operative anti-emetic usage, vital signs, onset and duration of sensory and motor block, the presence of adverse effects such as nausea and vomiting were recorded.

02

Conditions studied

  • Elective Reconstructive Surgery
  • Pain, Post Operative

Browse trials for

Keywords

  • free flap
  • nerve block
  • elective reconstructive surgery
  • dexmedetomidine
  • anterolateral thigh flaps
03

In context

Pain, Postoperative

5,095 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.

This study's planned enrollment of 60 is below the median of 75 across 4,346 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

This is the only study on the registry with Xia Zhang as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Prior diagnosis or presumed diagnosis of oral and maxillofacial tumor.
  • Undergoing microsurgical oromandibular reconstruction with free fibular flaps and anterolateral thigh flaps.
  • Greater than 18 years old.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

Exclusion Criteria:

  • True allergy to local anesthetics or opioids.
  • History of addiction to narcotics within the last 24 months
  • History of chronic pain on opioids within the last 24 months.
  • Specific mental health issues such as schizophrenia or bipolar disorder.
  • Patients who are pregnant.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Group PCA+B

    Both intravenous PCA and lower limb blocks were used. For patients with fibular flaps harvested, femoral nerve block and common peroneal nerve block with ropivacaine were administered. For patients with ALT flaps harvested, femoral nerve block with ropivacaine was administered.The interventions are femoral nerve block, common peroneal nerve block.

    Procedure: femoral nerve block, common peroneal nerve block

  • No intervention
    Group PCA

    Only intravenous patient controlled analgesia (PCA) was used postoperatively.

  • Experimental
    Group PCA+B+D

    Both intravenous PCA and lower limb blocks with dexmedetomidine as additivewere used.

    Procedure: femoral nerve block, common peroneal nerve block

Interventions

  • Procedurefemoral nerve block, common peroneal nerve block

    For patients with fibular flaps harvested, femoral nerve block and common peroneal nerve with ropivacaine were administered. For patients with ALT flaps harvested, femoral nerve block with ropivacaine was administered.

    Also known as: lower limb blocks with dexmedetomidine as additivewere

06

What researchers measure

Primary outcomes

  1. Post-operative Narcotic Usage

    Total intravenous sulfentanyl usage for rescue analgesia in first 48 hours post-operatively after free fibular flaps and anterolateral thigh flap reconstruction.

    Time frame: 48 hours

  2. duration of sensory blockade

    the time of sensory recovery

    Time frame: 48 hours

  3. duration of motor blockade

    the time of motor recovery

    Time frame: 48 hours

  4. onset of sensory blockade

    the time to sensory blockade

    Time frame: 48 hours

  5. onset of motor blockade

    the time to motor blockade

    Time frame: 48 hours

Secondary outcomes

  1. Post-operative Anti-emetic Usage

    Post-operative Anti-emetic Usage is defined as the total amount of IV tropisetron administered to a patient during the first 48 hours post-operatively.

    Time frame: 48 hours

  2. vital signs

    hear rate, blood pressure, SPO2

    Time frame: 48 hours

  3. Post-operative Pain Score

    Post-operative Pain Score is defined using Visual Analog Scale (VAS), a patient reported pain score on a scale of 0-10.

    Time frame: 48 hours

  4. adverse effects

    such as bradycardia, hypotension,respiratory depression, postoperative sedation

    Time frame: 48 hours

07

Study locations

1 of 1 sites recruiting
  • School & Hospital of Stomatology, China Medical University
    Shenyang, Liaoning 110002, China
    • xia zhang · Contact
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03071185
Lead sponsor
Xia Zhang
Responsible party
Xia Zhang (Associate Professor, China Medical University, China) — Sponsor-investigator
First posted
Mar 6, 2017
Start date
Jan 20, 2017
Primary completion
Nov 15, 2022 (estimated)
Completion
Nov 15, 2022 (estimated)
Last update
Nov 25, 2022

Study contacts

xia zhang, Ph.D.,MD
Contact
zhangxiamd@126.com
8624 31927811
xia zhang, Ph.D,MD
principal investigator · School & Hospital of Stomatology, China Medical University, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion